Filing Details

Accession Number:
0001209191-21-069415
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-12-14 16:18:00
Reporting Period:
2021-12-13
Accepted Time:
2021-12-14 16:18:00
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1434316 Fate Therapeutics Inc FATE Biological Products, (No Disgnostic Substances) (2836) 651311552
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1748177 Bahram Valamehr C/O Fate Therapeutics, Inc.
12278 Scripps Summit Drive
San Diego CA 92131
Chief R&D Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-12-13 25,000 $2.73 181,698 No 4 M Direct
Common Stock Disposition 2021-12-13 2,100 $45.68 179,598 No 4 S Direct
Common Stock Disposition 2021-12-13 7,018 $46.72 172,580 No 4 S Direct
Common Stock Disposition 2021-12-13 6,564 $47.61 166,016 No 4 S Direct
Common Stock Disposition 2021-12-13 7,718 $48.75 158,298 No 4 S Direct
Common Stock Disposition 2021-12-13 1,600 $49.27 156,698 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2021-12-13 25,000 $0.00 25,000 $2.73
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
61,156 2027-01-04 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020.
  2. Represents the weighted average sale price of the shares sold from $45.18 to $46.17 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 6.
  3. Represents the weighted average sale price of the shares sold from $46.20 to $47.17 per share.
  4. Represents the weighted average sale price of the shares sold from $47.21 to $48.20 per share.
  5. Represents the weighted average sale price of the shares sold from $48.21 to $49.20 per share.
  6. Represents the weighted average sale price of the shares sold from $49.21 to $49.40 per share.
  7. This option is fully vested.